| Treat-to-target in systemic lupus erythematosus: recommendations from an international task force RF Van Vollenhoven, M Mosca, G Bertsias, D Isenberg, A Kuhn, ... Annals of the rheumatic diseases 73 (6), 958-967, 2014 | 796 | 2014 |
| A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS) R Van Vollenhoven, A Voskuyl, G Bertsias, C Aranow, M Aringer, ... Annals of the rheumatic diseases 76 (3), 554-561, 2017 | 370 | 2017 |
| A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from … DH Yoo, A Racewicz, J Brzezicki, R Yatsyshyn, ET Arteaga, ... Arthritis research & therapy 18, 1-12, 2016 | 200 | 2016 |
| 2021 DORIS definition of remission in SLE: final recommendations from an international task force RF van Vollenhoven, G Bertsias, A Doria, D Isenberg, E Morand, MA Petri, ... Lupus Science & Medicine 8 (1), e000538, 2021 | 150 | 2021 |
| Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study V Golder, R Kandane-Rathnayake, AYB Hoi, M Huq, W Louthrenoo, Y An, ... Arthritis research & therapy 19, 1-11, 2017 | 133 | 2017 |
| How do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new … M Mosca, KH Costenbader, SR Johnson, V Lorenzoni, GD Sebastiani, ... Arthritis & Rheumatology 71 (1), 91-98, 2019 | 129 | 2019 |
| Impact of systemic lupus erythematosus on health, family, and work: the patient perspective D Robinson Jr, D Aguilar, M Schoenwetter, R Dubois, S Russak, ... Arthritis Care & Research: Official Journal of the American College of …, 2010 | 100 | 2010 |
| Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort V Golder, R Kandane-Rathnayake, AYB Hoi, M Huq, W Louthrenoo, Y An, ... Arthritis research & therapy 18, 1-9, 2016 | 56 | 2016 |
| Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study D Apostolopoulos, R Kandane-Rathnayake, W Louthrenoo, SF Luo, ... The Lancet Rheumatology 2 (1), e24-e30, 2020 | 55 | 2020 |
| OP0068 A phase 3 randomised controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54 week results from the planetra study DH Yoo, A Racewicz, J Brzezicki, R Yatsyshyn, ET Arteaga, ... Annals of the Rheumatic Diseases 72 (Suppl 3), A73-A73, 2013 | 42 | 2013 |
| The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus CC Mok, L Hamijoyo, N Kasitanon, S Chen, K Yamaoka, K Oku, MT Li, ... The Lancet Rheumatology 3 (7), e517-e531, 2021 | 36 | 2021 |
| Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre … SZ Sheikh, MA Scheinberg, JCC Wei, D Tegzova, W Stohl, RA de Toledo, ... The Lancet Rheumatology 3 (2), e122-e130, 2021 | 27 | 2021 |
| Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study V Golder, M Huq, K Franklyn, A Calderone, A Lateef, CS Lau, ALH Lee, ... Seminars in arthritis and rheumatism 46 (6), 798-803, 2017 | 21 | 2017 |
| Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study R Kandane-Rathnayake, W Louthrenoo, V Golder, SF Luo, YJJ Wu, ... Rheumatology 60 (11), 5185-5193, 2021 | 17 | 2021 |
| Successful use of diltiazem in calcinosis caused by connective tissue disease TP Torralba, J Li-Yu, STGV Navarra JCR: Journal of Clinical Rheumatology 5 (2), 74-78, 1999 | 17 | 1999 |
| Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison HI Brunner, C Abud-Mendoza, M Mori, CA Pilkington, R Syed, S Takei, ... Rmd Open 7 (3), e001747, 2021 | 15 | 2021 |
| COVID‐19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration J Cho, R Kandane‐Rathnayake, W Louthrenoo, A Hoi, V Golder, ... International Journal of Rheumatic Diseases 23 (9), 1255, 2020 | 15 | 2020 |
| Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements K Oku, L Hamijoyo, N Kasitanon, MT Li, S Navarra, E Morand, Y Tanaka, ... International Journal of Rheumatic Diseases 24 (7), 880-895, 2021 | 14 | 2021 |
| Development and implementation of Models of Care for musculoskeletal conditions in middle-income and low-income Asian countries KK Lim, M Chan, S Navarra, SA Haq, CS Lau Best Practice & Research Clinical Rheumatology 30 (3), 398-419, 2016 | 14 | 2016 |
| Management of non‐renal manifestations of systemic lupus erythematosus: a systematic literature review for the APLAR consensus statements N Kasitanon, L Hamijoyo, MT Li, K Oku, S Navarra, Y Tanaka, CC Mok International Journal of Rheumatic Diseases 25 (11), 1220-1229, 2022 | 11 | 2022 |
